Stock Scorecard
Stock Summary for Pulmonx Corp (LUNG) - $7.66 as of 4/25/2024 4:30:31 PM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LUNG
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LUNG
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LUNG
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for LUNG
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for LUNG
Financial Details for LUNG
Company Overview |
|
---|---|
Ticker | LUNG |
Company Name | Pulmonx Corp |
Country | USA |
Description | Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California. |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/1/2024 |
Stock Price History |
|
Last Day Price | 7.66 |
Last Day Price Updated | 4/25/2024 4:30:31 PM EST |
Last Day Volume | 198,804 |
Average Daily Volume | 492,279 |
52-Week High | 14.84 |
52-Week Low | 7.21 |
Last Price to 52 Week Low | 6.24% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 48.36 |
Sector PE | 61.73 |
5-Year Average PE | -9.37 |
Free Cash Flow Ratio | 3.56 |
Industry Free Cash Flow Ratio | 61.97 |
Sector Free Cash Flow Ratio | 30.74 |
Current Ratio Most Recent Quarter | 6.50 |
Total Cash Per Share | 2.15 |
Book Value Per Share Most Recent Quarter | 3.07 |
Price to Book Ratio | 2.59 |
Industry Price to Book Ratio | 5.21 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 4.46 |
Industry Price to Sales Ratio Twelve Trailing Months | 14.23 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 38,811,800 |
Market Capitalization | 297,298,388 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -3.26% |
Reported EPS 12 Trailing Months | -1.60 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -1.60 |
Net Income Twelve Trailing Months | -60,843,000 |
Net Income Past Year | -60,843,000 |
Net Income Prior Year | -58,923,000 |
Quarterly Revenue Growth YOY | 25.00% |
5-Year Revenue Growth | 34.41% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 83,547,000 |
Total Cash Past Year | 83,547,000 |
Total Cash Prior Year | 141,138,000 |
Net Cash Position Most Recent Quarter | 46,303,000 |
Net Cash Position Past Year | 46,303,000 |
Long Term Debt Past Year | 37,244,000 |
Long Term Debt Prior Year | 17,324,000 |
Total Debt Most Recent Quarter | 37,244,000 |
Equity to Debt Ratio Past Year | 0.76 |
Equity to Debt Ratio Most Recent Quarter | 0.76 |
Total Stockholder Equity Past Year | 118,315,000 |
Total Stockholder Equity Prior Year | 154,007,000 |
Total Stockholder Equity Most Recent Quarter | 118,315,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.64 |
MACD Signal | -0.62 |
20-Day Bollinger Lower Band | 6.72 |
20-Day Bollinger Middle Band | 11.19 |
20-Day Bollinger Upper Band | 15.66 |
Beta | 0.60 |
RSI | 28.13 |
50-Day SMA | 11.29 |
200-Day SMA | 0.00 |
System |
|
Modified | 4/25/2024 5:10:55 AM EST |